Proteostasis Therapeutics, which is developing combination therapeutics that use amplifier molecules to modulate proteins, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company, which was founded in 2006 and booked $4 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol PTI. Proteostasis Therapeutics filed confidentially on 5/8/2015. Leerink Partners, RBC Capital Markets, Baird and H.C. Wainwright are the joint bookrunners on the deal. No pricing terms were disclosed.
